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Background: Assessing of the costs of treating disease is necessary to demonstrate cost-effectiveness and to estimate
the budget impact of new interventions and therapeutic innovations. However, there are few comprehensive studies
on resource use and costs associated with lung cancer patients in clinical practice in Spain or internationally. The aim of
this paper was to assess the hospital cost associated with lung cancer diagnosis and treatment by histology, type of
cost and stage at diagnosis in the Spanish National Health Service.
Methods: A retrospective, descriptive analysis on resource use and a direct medical cost analysis were performed.
Resource utilisation data were collected by means of patient files from nine teaching hospitals. From a hospital
budget impact perspective, the aggregate and mean costs per patient were calculated over the first three years
following diagnosis or up to death. Both aggregate and mean costs per patient were analysed by histology, stage
at diagnosis and cost type.
Results: A total of 232 cases of lung cancer were analysed, of which 74.1% corresponded to non-small cell lung
cancer (NSCLC) and 11.2% to small cell lung cancer (SCLC); 14.7% had no cytohistologic confirmation. The mean
cost per patient in NSCLC ranged from 13,218 Euros in Stage III to 16,120 Euros in Stage II. The main cost components
were chemotherapy (29.5%) and surgery (22.8%). Advanced disease stages were associated with a decrease in the
relative weight of surgical and inpatient care costs but an increase in chemotherapy costs. In SCLC patients, the
mean cost per patient was 15,418 Euros for limited disease and 12,482 Euros for extensive disease. The main cost
components were chemotherapy (36.1%) and other inpatient costs (28.7%). In both groups, the Kruskall-Wallis test
did not show statistically significant differences in mean cost per patient between stages.
Conclusions: This study provides the costs of lung cancer treatment based on patient file reviews, with chemotherapy
and surgery accounting for the major components of costs. This cost analysis is a baseline study that will provide a
useful source of information for future studies on cost-effectiveness and on the budget impact of different therapeutic
innovations in Spain.
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Lung cancer is the third most commonly diagnosed can-
cer in Spain, with approximately 32,240 newly diagnosed
cases and 21,120 deaths from the disease each year. In
Europe, lung cancer is also the most common cause of
cancer death, with 353,460 deaths in 2012 [1].
In recent years, new drugs have been developed for lung
cancer treatment, promising potential advances for patient
outcomes [2]. The need to demonstrate cost-effectiveness
and estimate the budget impact of new interventions and
therapeutic innovations requires consideration of the costs
of treating disease, including all therapeutic strategies,
namely surgery, chemotherapy and radiotherapy.
However, there are very few comprehensive studies on
resource use and costs associated with lung cancer pa-
tients in clinical practice in Spain or internationally. Some
studies have examined the costs of lung cancer treatment,
but they were based on older treatment pathways [3,4] or
on simplified clinical algorithms, not on reviews of patient
records [5]. Because recently introduced drugs have sig-
nificantly increased the cost of the treatment [6], some
studies have focused on chemotherapy treatments or on a
particular phase of the disease [7-11]. A few studies have
also analysed hospital costs of cancer treatment by stage at
diagnosis [3,4,12,13].
It is very important to assess the cost of the entire
treatment regime, not only of one therapy, in order to
offer a proper perspective on the economic impact of all
therapeutic strategies. The aim of this paper is to assess
the hospital costs associated with lung cancer diagnosis
and treatment by histology, type of cost and stage at diag-
nosis in the Spanish National Health Service context.
Methods
Patients
There are 53 public hospitals treating lung cancer patients
at all stages of the disease in Catalonia; 10 hospitals
(19%) have a thoracic surgery unit. As part of a global
programme to assess cancer treatment in Catalonia, a
clinical audit of lung cancer treatment was conducted
on 1,186 incident patients from 23 hospitals that had a
volume of at least 20 cases per year. For our study, a
subset of 232 patients from the main patient sample
was randomly selected from the 9 teaching hospitals
(out of the 10 with a thoracic surgery unit) that diagnose
over 50 patients per year; these hospitals also had informa-
tion on their resource use available through electronic
records. The sample size is composed of 197 patients
diagnosed with non-small cell lung cancer (NSCLC) and
35 patients diagnosed with small cell lung cancer (SCLC),
providing 80% power to detect as significant a difference
of 2,000 Euros in the mean cost by stages in NSCLC
patients, and 5,000 Euros in the mean cost by stages in
SCLC patients. The power calculation was based on theassumption of a standard deviation of 5,250 Euros for
NSCLC, and a standard deviation of 4,500 Euros for
SCLC patients, using two-sided tests at a significance level
of 0.05. All assumptions were based on previous studies
[3,13]. Random samples were drawn proportionally to the
percentage of patients diagnosed at each hospital in 2008.
The Minimum Basic Data Set (MBDS) was the source of
information available for the selection of cases.
Patients were categorised based on histology as either
NSCLC or SCLC. When histology was unrecorded, patients
fell into the category of “no cytohistologic confirmation”
(NCC). NSCLC patients were classified by TNM stage at
diagnosis [14] (regardless of the disease progression during
treatment). SCLC patients were classified as having limited
or extensive disease.
The permission to access the patient files was given
by the Catalan Health Service (Department of Health
of Catalonia). Approval for this study was given by the
Clinical Research Ethics Committee of the Bellvitge
University Hospital, since it was the referral Ethics
Committee of the study coordinating institution.
Patient-level analysis and cost estimation
A retrospective, descriptive analysis on resource use and
a direct medical cost analysis were carried out. Resource
utilisation data were collected by means of hospital ad-
ministrative databases and patient files. From a hospital
budget impact perspective, the aggregate and mean costs
per patient were assessed in the three years following
diagnosis or up to death. Both aggregate and mean costs
per patient were analysed by stage at diagnosis and cost
type. Mean cost per patient was also analysed by sex, age
group and survival at one year from diagnosis. The
categories of cost considered included (a) diagnosis
(diagnostic tests, ambulatory and emergency visits, in-
patient nights), (b) surgery (operating room and inpatient
nights), (c) chemotherapy (day hospital and cytotoxic
drugs), (d) radiotherapy (number of fractions), (e) other
inpatient care (not related to diagnosis, surgery, chemo-
therapy or radiotherapy treatments for lung cancer, e.g.,
hospital admissions related to COPD or other comor-
bidities and palliative care), and (f ) continuing care
(ambulatory and emergency visits, tests, scans, biopsies,
etc., made in the continuing phase). The mean costs of
surgical interventions as well as chemotherapy and radio-
therapy treatments were also assessed by histology and
stage at diagnosis.
To assess the cost of the episodes of care in the period
considered, unit costs from 2008 were obtained from two
sources: from one hospital (Hospital del Mar) with a
detailed analytical accounting system implemented over
10 years ago, and from the Spanish Network of Hospital
Costs Database (RECH), which has data from 13 hospi-
tals in Spain and it has been registered and accredited
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diagnosis was considered the baseline year (Year 0)
with costs from later calendar years being discounted at
3%.
Statistical analysis
A descriptive summary of the patients’ characteristics was
formulated, reporting age, gender, TNM stage at diagnosis
and treatment received. Kaplan-Maier estimates of sur-
vival time were stratified by histology and stage at diagno-
sis. A descriptive analysis was done to evaluate aggregate
and mean cost per patient. Mann–Whitney tests were
used to identify mean cost differences between sex (male/
female), age group (<65 years/≥65 years) and survival at
one year from diagnosis (alive one year/dead one year);
and Kruskal-Wallis tests were performed to identify differ-
ences between stages. In addition, a descriptive analysis of
mean costs of surgical, chemotherapy and radiotherapy
treatments were carried out. All calculations were made
using SPSS for Windows 21.0.
Results
Patient characteristics and survival
A total of 232 cases of lung cancer were analysed, of
which 172 (74.1%) were NSCLC and 26 (11.2%) were
SCLC; 34 (14.7%) had no cytohistologic confirmation.
Table 1 describes age, gender, staging distribution of pa-
tients at diagnosis and treatments received.
The median survival time was not estimable in Stages
I, II (Table 2). The mean survival time decreased in
NSCLC patients from Stage I to IV ranging from 36.3 to
10.7 months and in SCLC patients between limited dis-
ease and extensive disease from 17.0 to 9.4 months.
Cost estimation
Table 3 shows the aggregate costs of treatment by hist-
ology, stage at diagnosis, and cost category over the three
years following diagnosis or up to death. In NSCLC cases,
the aggregate hospital cost of lung cancer treatment
ranged from 177,320 Euros at Stage II to 1,068,133 Euros
at Stage IV. The aggregated cost in Stage IV was the high-
est, representing 41.9% of the total cost. In SCLC cases,
the aggregate cost for limited disease was assessed at
107,929 Euros, whereas the cost for extensive disease was
assessed as 199,707 Euros, representing 61.6% of the total
cost.
Table 4 shows the mean cost per patient of lung cancer
treatment by histology, sex, age group, stage at diagnosis,
survival at one year from diagnosis and cost type. Mean
cost per patient in NSCLC ranged from 13,218 Euros in
Stage III to 16,120 Euros in Stage II. The main cost com-
ponents in global mean cost per patient in NSCLC were
chemotherapy (29.5%) and surgery (22.8%). The surgical
and inpatient care cost represented 58.9% in Stage I, whilein Stage II it was 45.9%, decreasing its relative weight as
disease stage progressed. In addition, the relative chemo-
therapy cost increased in more advanced stages from 5.2%
in Stage I to 45.7% in Stage IV. The relative cost of other
inpatient care not related to lung cancer, including comor-
bid diseases, was stable between stages.
In SCLC patients, the mean cost per patient with limited
disease was 15,418 Euros, whereas the mean cost per pa-
tient with extensive disease was 12,482 Euros. The main
cost components in the global mean cost per patient in
SCLC were chemotherapy (36.1%) and other inpatient
costs (28.7%).
Whereas large qualitative differences were observed be-
tween stages with regard to the aggregrate cost of treat-
ment, the Kruskall-Wallis test did not show any statistically
significant cost differences between stages in the mean
cost per patient in the NSCLC, SCLC and NCC groups
(p-value = 0.289, 0.140 and 0.231, respectively). Mann–
Whitney tests showed statistically significant cost dif-
ferences between patients who did or did not survive at
one year from diagnosis in NSCLC cases (p-value = 0.002)
and between age groups in SCLC and NCC patients
(p-value = 0.006 and 0.009 respectively).
Table 5 shows the mean cost of surgical, chemotherapy
and radiotherapy treatments by histology and stage at
diagnosis. In NSCLC, the mean cost of surgical interven-
tions ranged from 7,621 Euros in Stage IV to 10,228 Euros
in Stage III. The mean cost of chemotherapy treatment
ranged from 1,949 Euros in Stage I to 7,179 Euros in Stage
IV. The mean cost of radiotherapy ranged from 663 Euros
in Stage IV to 1,308 Euros in Stage II. In SCLC patients,
the global mean cost of chemotherapy and radiotherapy
treatments were 3,778 Euros and 943 Euros, respect-
ively. In NCC patients, the global mean cost of surgical
interventions, and chemotherapy and radiotherapy treat-
ments were assessed at 8,835 Euros, 6,988 Euros and 791
Euros, respectively. Regardless of the histology, high vari-
ability was observed in the mean cost of chemotherapy
treatments.
Discussion
In this multicentre study, we assessed hospital costs of
lung cancer diagnosis and treatment in 232 patients from
9 hospitals in Catalonia. There were 53 public hospitals, of
which only 10 had a thoracic surgery unit. The 9 hospitals
selected from this study were taken from this group.
Therefore, this sample selection was considered to be rep-
resentative of teaching surgical hospitals in Catalonia.
The results of this study show that there is no associ-
ation between the mean cost per patient and the stage of
the disease. Indeed, there were no statistical significant
differences in the mean cost per patient between stages.
In NSCLC, surgery, diagnosis, chemotherapy and other
inpatient care were the main components of the mean
Table 1 Patient characteristics
NSCLC SCLC NCC Total
N 172 26 34 232
Age (years), mean 65.4 67.3 72.7 66.7
Gender (%)
Male 84.9 88.5 73.5 83.6
Female 15.1 11.5 26.5 16.4
TNM Stage (%)
I 22.7 - 5.9 -
II 6.4 - - -
III 20.9 - 11.8 -
IV 41.3 - 47.1 -
Limited disease - 26.9 - -
Extensive disease - 61.5 - -
Unknown 8.7 11.5 35.3 -
Surgery (%) 34.9 - 11.8 27.6
Partial lobectomy 3.3 - 25.0 4.6
Lobectomy 59. - 75.0 60.0
Bilobectomy 11.5 - - 10.8
Pneumonectomy 9.8 - - 9.2
Exploratory thoracotomy 8.2 - - 7.7
Others 8.2 - - 7.7
Chemotherapy (%) 53.5 80.8 20.6 51.7
Intention
Neoadjuvant 3.0 - - 2.2
Adjuvant 5.9 - - 4.5
Radical 8.8 25.9 - 11.2
Palliative 45.2 41.9 46.2 44.7
Unknown 37.0 32.3 53.8 37.4
Treatment scheme
Cisplatin/Carboplatin + Docetaxel 5.9 - 7.7 5.0
Cisplatin/Carboplatin + Etoposide 6.7 67.7 - 16.8
Cisplatin/Carboplatin + Gemcitabine 23.7 - 7.7 18.4
Cisplatin/Carboplatin + Paclitaxel 6.7 3.2 15.4 6.7
Cisplatin/Carboplatin + Pemetrexed 5.9 - 7.7 5.0
Cisplatin/Carboplatin + Vinorelbine 16.3 - 7.7 12.8
Docetaxel 4.4 - 7.7 3.9
Erlotinib 11.9 3.2 15.4 10.6
Pemetrexed 8.1 - 15.4 7.3
Others 10.3 25.8 15.4 13.4
Radiotherapy (%) 35.5 69.2 8.8 35.3
Radical 31.0 20.8 0.0 26.8
Palliative 53.5 50.0 83.3 54.4
Unknown 15.5 29.2 16.7 18.8
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Table 2 Survival time by histology and stage at diagnosis
N Deaths N (%) Survival time (months)Median
Survival time (months)
Mean [sd]
Follow-up time (months)
Mean [sd]
NSCLC
Stage I 39 6 (15.4) - 36.3 [2.2] 21.2 [13.1]
Stage II 11 3 (27.3) - 32.1 [3.9] 21.5 [13.3]
Stage III 36 17 (47.2) 16.0 18.9 [2.8] 11.9 [11.4]
Stage IV 71 44 (62.0) 4.9 10.7 [1.9] 5.6 [7.9]
Unknown 15 5 (33.3) - 20.1 [4.5] 10.1 [12.1]
Total 172 75 (43.6) 18.0 22.8 [1.6] 11.9 [12.5]
SCLC
Limited disease 7 4 (57.1) 10.9 17.0 [3.6] 12.6 [7.1]
Extensive disease 16 13 (81.3) 8.6 9.4 [2.5] 8.4 [9.1]
Unknown 3 2 (66.7) 1.1 1.3 [0.4] 1.3 [1.0]
Total 26 19 (73.1) 8.9 11.8 [2.6] 8.7 [8.5]
NCC
Stage I 2 0 (0.0) - - 36.3 [0.2]
Stage II - - - - -
Stage III 4 2 (50.0) - - 11.9 [13.6]
Stage IV 16 11 (68.8) - - 4.8 [8.7]
Unknown 12 3 (25.0) - - 1.8 [2.1]
Total 34 16 (47.1) - - 6.4 [10.9]
NSCLC: non-small cell lung cancer.
SCLC: small cell lung cancer.
NCC: No cytohistologic confirmation.
sd: standard deviation.
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not as high as expected because of the type of drug
schemes used at that time. While the costs of Stages II
and IV were quite similar, the relative weight of surgery
and chemotherapy cost was higher in Stage II. As ex-
pected, and in accordance with clinical guidelines [17],
advanced disease stages were associated with a decrease
in the relative weight of surgery, but an increase in
chemotherapy costs. This pattern was also observed in
the mean costs of chemotherapy treatments received.
In the final balance, these different costs may cancel
each other out, explaining why no association was ob-
served between mean cost per patient and the stage of
the disease. For SCLC patients, chemotherapy was one
of the main components of the mean cost per patient.
In both NSCLC and SCLC, the cost of other inpatient
care was relatively important in terms of global mean
cost per patient at all stages. This might be due to the
comorbidity associated with these tumours.
In NSCLC cases, a statistical difference between the
mean cost of patients surviving one year from diagnosis
and those who died was observed, so among other reasons,
cost differences might also be explained by their different
lengths of survival. In SCLC patients, this difference was
also observed, although it was not statistically significant.In SCLC and NCC patients there were differences in the
mean cost per patient between age groups, with older
groups incurring more costs. This suggests that these pa-
tients had a higher comorbidity, perhaps due to their more
advanced age.
In the last ten years, various studies have estimated
the cost of lung cancer treatment, with different objec-
tives, methodologies and health contexts. Most of these
studies have analysed cost components, but their find-
ings are not directly comparable because resource use is
not classified into the same cost categories as in our
study. However, using similar methodology, in the study
carried out by Kang et al. [13], the relative weight of
chemotherapy costs in the total mean cost per patient in
NSCLC is similar to our findings, ranging from 5% in
Stage I to 33% in Stage IV. However, in SCLC patients
their results are lower than ours. Dedes et al. [4] did not
distinguish between NSCLC and SCLC, and they found
that the largest cost item corresponded to hospitalisation
(71% of total cost). They also found that chemotherapy
was responsible for 14% of the total cost.
Only a few studies have analysed the hospital cost of
lung cancer treatment by stage at diagnosis. In the study
carried out by Fleming et al. [12], the researchers found
that the stage at diagnosis had a significant influence on
Table 3 Aggregate hospital costs of lung cancer diagnosis and treatment by stage at diagnosis and cost type (Euros, 2008)
Diagnosis Surgery Chemotherapy Radiotherapy Other inpatient care Continuing care Total cost
NSCLC (sum, %)
Stage I 28,573 306,114 27,280 12,755 102,652 42,153 519,526
5.5% 58.9% 5.3% 2.5% 19.8% 8.1% 100.0%
Stage II 16,106 81,416 27,624 6,538 32,288 13,348 177,320
9.1% 45.9% 15.6% 3.7% 18.2% 7.5% 100.0%
Stage III 119,463 71,598 98,958 25,969 128,901 30,957 475,846
25.1% 15.0% 20.8% 5.5% 27.1% 6.5% 100.0%
Stage IV 287,012 22,863 488,195 23,205 227,928 18,930 1,068,133
26.9% 2.1% 45.7% 2.2% 21.3% 1.8% 100.0%
Unknown 71,792 98,615 111,030 900 15,828 9,670 307,835
23.3% 32.0% 36.1% 0.3% 5.1% 3.1% 100.0%
Total (N = 172) 522,946 580,605 753,087 69,367 507,597 115,058 2,548,661
20.5% 22.8% 29.5% 2.7% 19.9% 4.5% 100.0%
SCLC (sum, %)
Limited disease 11,822 - 33,959 11,699 42,933 7,516 107,929
11.0% 31.5% 10.8% 39.8% 7.0% 100.0%
Extensive disease 45,011 - 83,077 10,928 48,729 11,962 199,707
22.5% 41.6% 5.5% 24.4% 6.0% 100.0%
Unknown 14,584 - 67 - 1,266 526 16,444
88.7% 0.4% 7.7% 3.2% 100.0%
Total (N = 26) 71,417 - 117,103 22,627 92,928 20,005 324,079
22.0% 36.1% 7.0% 28.7% 6.2% 100.0%
NCC (sum, %)
Stage I 2,195 16,844 - - 83,428 701 103,168
2.1% 16.3% 80.9% 0.7% 100.0%
Stage II - - - - - - -
Stage III 8,122 - 7,400 - 5,875 1,880 23,277
34.9% 31.8% 25.2% 8.1% 100.0%
Stage IV 58,543 7,835 81,106 4,747 32,462 2,973 187,665
31.2% 4.2% 43.2% 2.5% 17.3% 1.6% 100.0%
Unknown 62,873 10,660 2,335 - 20,794 1,698 98,360
63.9% 10.8% 2.4% 21.1% 1.7% 100.0%
Total (N = 34) 131,734 35,339 90,841 4,747 142,559 7,252 412,472
31.9% 8.6% 22.0% 1.2% 34.6% 1.8% 100.0%
NSCLC: non-small cell lung cancer.
SCLC: small cell lung cancer.
NCC: no cytohistologic confirmation.
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lower when disease presentation was at an advanced stage,
reflecting the shorter survival and lower tolerance to ag-
gressive treatment among these patients, as well as the
more limited treatment options available to them. On the
other hand, increasing costs in advanced stages of the dis-
ease have been observed in other studies [13].
Our findings on the influence of the stage at diagnosis in
mean cost per patient are consistent with those presentedby Demeter et al. [3], where there was no clear correlation
between mean cost per patient and stage at diagnosis.
We were not able to identify any study similar to ours
in Spain. The study carried out by Isla et al. [5] analysed
treatment patterns, use of resources and costs of ad-
vanced NSCLC patients and was based on consensus
recommendations of different chemotherapy schemes. The
results reported are much higher than in our study because
they are not based on clinical practice; rather, they are
Table 4 Mean hospital costs of lung cancer diagnosis and treatment per patient by sex, age group, stage at diagnosis,
survival at one year from diagnosis and cost type (Euros, 2008)
Diagnosis Surgery Chemotherapy Radiotherapy Otherinpatient care
Continuing
care
Total mean
cost p-value
NSCLC (mean, [sd], %)
Male 2,998 [3,264] 3,272 [4,838] 3,261 [8,354] 432 [785] 2,982 [4,805] 678 [910] 13,624 [10,649]
0.072
(N = 146) 22.0% 24.0% 23.9% 3.2% 21.9% 5.0% 100.0%
Female 3,277 [3,089] 3,955 [5,542] 10,654 [19,139] 242 [595] 2,777 [4,738] 616 [979] 21,521 [19,367]
(N = 26) 15.2% 18.4% 49.5% 1.1% 12.9% 2.9% 100%
<65 years 2,880 [3,058] 3,436 [5,338] 4,890 [10,060] 403 [740] 2,981 [5,078] 679 [906] 15,270 [12,600]
0.716
(N = 76) 18.9% 22.5% 32.0% 2.6% 19.5% 4.4% 100.0%
≥65 years 3,167 [3,372] 3,327 [4,628] 3,973 [11,634] 403 [781] 2,928 [4,561] 661 [932] 14,460 [12,674]
(N = 96) 21.9% 23.0% 27.5% 2.8% 20.2% 4.6% 100.0%
Stage I 733 [551] 7,849 [4,515] 699 [2,179] 327 [745] 2,632 [5,285] 1,081 [864] 13,321 [8,316]
0.289
(N = 39) 5.5% 58.9% 5.2% 2.5% 19.8% 8.1% 100.0%
Stage II 1,464 [1,131] 7,401 [4,898] 2,511 [4,887] 594 [811] 2,935 [4,142] 1,213 [1,333] 16,120 [7,632]
(N = 11) 9.1% 45.9% 15.6% 3.7% 18.2% 7.5% 100.0%
Stage III 3,318 [2,576] 1,989 [4,159] 2,749 [6,452] 721 [978] 3,581 [5,051] 860 [1,235] 13,218 [10,240]
(N = 36) 25.1% 15.0% 20.8% 5.5% 27.1% 6.5% 100.0%
Stage IV 4,042 [3,299] 322 [1,610] 6,876 [13,283] 327 [661] 3,210 [4,853] 263 [416] 15,044 [14,338]
(N = 71) 26.9% 2.1% 45.7% 2.2% 21.3% 1.7% 100.0%
Unknown 4,786 [5,423] 6,574 [6,133] 7,402 [18,928] 60 [232] 1,055 [2,059] 645 [833] 20,522 [19,336]
(N = 15) 23.3% 32.0% 36.1% 0.3% 5.1% 3.1% 100.0%
Alive 1 year 2,644 [3,138] 4,814 [5,372] 4,427 [10,847] 472 [812] 2,661 [4,477] 938 [1,038] 15,955 [12,202]
0.002
(N = 106) 16.6% 30.2% 27.7% 3.0% 16.7% 5.9% 100.0%
Dead 1 year 3,677 [3,300] 1,066 [2,961] 4,301 [11,183] 293 [661] 3,418 [5,237] 237 [409] 12,991 [13,129]
(N = 66) 28.3% 8.2% 33.1% 2.3% 26.3% 1.8% 100.0%
Total 3,040 [3,231] 3,376 [4,939] 4,378 [10,945] 403 [761] 2,951 [4,782] 669 [918] 14,818 [12,611]
(N = 172) 20.5% 22.8% 29.5% 2.7% 19.9% 4.5% 100.0%
SCLC (mean, [sd], %)
Male 2,708 [2,350] - 4,646 [10,164] 878 [952] 2,747 [3,627] 694 [791] 11,674 [11,089]
0.078
(N = 23) 23.2% 39.8% 7.5% 23.5% 5.9% 100.0%
Female 3,041 [1,905] - 3,412 [2,889] 814 [912] 9,915 [8,846] 1,345 [1,272] 18,527 [9,054]
(N = 3) 16.4% 18.4% 4.4% 53.5% 7.3% 100.0%
<65 years 2,159 [1,993] - 7,361 [13,510] 1,114 [981] 5,580 [6,000] 1,080 [930] 17,294 [14,093]
0.006
(N = 12) 12.5% 42.6% 6.4% 32.3% 6.2% 100.0%
≥65 years 3,251 [2,443] - 2,055 [2,824] 661 [864] 1,855 [2,726] 503 [706] 8,325 [4,718]
(N = 14) 39.1% 24.7% 7.9% 22.3% 6.0% 100.0%
Limited disease 1,689 [1,757] - 4,851 [3,380] 1,671 [1,187] 6,133 [7,057] 1,074 [867] 15,418 [10,105]
0.140
(N = 7) 11.0% 31.5% 10.8% 39.8% 7.0% 100.0%
Extensive disease 2,813 [2,175] - 5,192 [11,989] 683 [624] 3,046 [3,672] 748 [888] 12,482 [12,007]
(N = 16) 22.5% 41.6% 5.5% 24.4% 6.0% 100.0%
Unknown 4,861 [3,018] - 22 [39] - 422 [731] 175 [208] 5,481 [2,378]
(N = 3) 88.7% 0.4% 7.7% 3.2% 100.0%
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Table 4 Mean hospital costs of lung cancer diagnosis and treatment per patient by sex, age group, stage at diagnosis,
survival at one year from diagnosis and cost type (Euros, 2008) (Continued)
Alive 1 year 2,388 [2,047] - 2,976 [2,784] 1,436 [1,093] 1,431 [2,652] 1,086 [1,008] 9,316 [3,443]
0.597
(N = 9) 25.6% 31.9% 15.4% 15.4% 11.7% 100.0%
Dead 1 year 2,937 [2,420] - 5,313 [11,724] 571 [692] 4,709 [5,378] 602 [735] 14,131 [13,140]
(N = 17) 20.8% 37.6% 4.0% 33.3% 4.3% 100.0%
Total 2,747 [2,272] - 4,504 [9,578] 870 [930] 3,574 [4,826] 769 [852] 12,465 [10,943]
(N = 26) 22.0% 36.1% 7.0% 28.7% 6.2% 100.0%
NCC (mean, [sd], %)
Male 3,901 [3,538] 1,100 [3,063] 183 [533] 36 [136] 4,768 [16,839] 129 [254] 10,116 [18,410]
0.645
(N = 25) 38.6% 10.9% 1.8% 0.4% 47.1% 1.3% 100.0%
Female 3,802 [2,945] 871 [2,612] 9,586 [17,920] 427 [1,282] 2,597 [4,336] 447 [604] 17,729 [23,745]
(N = 9) 21.4% 4.9% 54.1% 2.4% 14.6% 2.5% 100.0%
<65 years 2,961 [3,609] 3,085 [4,261] 10,040 [19,035] 513 [1,350] 14,563 [28,241] 293 [476] 31,455 [34,191]
0.009
(N = 8) 9.4% 9.8% 31.9% 1.6% 46.3% 0.9% 100.0%
≥65 years 4,156 [3,286] 410 [2,091] 405 [1,504] 25 [126] 1,002 [3,338] 189 [373] 6,186 [6,128]
(N = 26) 67.2% 6.6% 6.5% 0.4% 16.2% 3.1% 100.0%
Stage I 1,098 [998] 8,422 [0] - - 41,714 [58,992] 350 [496] 51,584 [59,495]
0.231
(N = 2) 2.1% 16.3% 80.9% 0.7% 100.0%
Stage II - - - - - - -
(N = 0)
Stage III 2,031 [2,498] - 1,850 [3,700] - 1,469 [1,300] 470 [550] 5,819 [6,680]
(N = 4) 34.9% 31.8% 25.2% 8.1% 100.0%
Stage IV 3,659 [2,869] 490 [1,959] 5,069 [13,981] 297 [962] 2,029 [4,090] 186 [436] 11,729 [18,728]
(N = 16) 31.2% 4.2% 43.2% 2.5% 17.3% 1.6% 100.0%
Unknown 5,239 [3,984] 888 [3,077] 195 [674] - 1,733 [4,840] 142 [261] 8,197 [7,585]
(N = 12) 64.1% 10.8% 2.4% 21.1% 1.7% 100.0%
Alive 1 year 3,493 [2,978] 1,860 [3,735] 2,088 [6,677] 216 [881] 5,861 [19,080] 333 [478] 13,851 [22,728]
0.242
(N = 19) 25.2% 13.4% 15.1% 1.6% 42.3% 2.4% 100.0%
Dead 1 year 4,358 [3,816] - 3,411 [12,939] 43 [166] 2,080 [4,734] 62 [171] 9,954 [16,042]
(N = 15) 43.8% 34.3% 0.4% 20.9% 0.6% 100.0%
Total 3,875 [3,348] 1,039 [2,914] 2,672 [9,787] 140 [666] 4,193 [14,550] 213 [394] 12,132 [19,869]
(N = 34) 31.9% 8.6% 22.0% 1.2% 34.6% 1.8% 100.0%
NSCLC: non-small cell lung cancer.
SCLC: small cell lung cancer.
NCC: no cytohistologic confirmation.
sd: standard deviation.
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do not take into account the variability of clinical practice.
Another study carried out by Arca et al. Y analysed the
costs of lung cancer diagnosis. They found that the mean
cost for diagnosing NSCLC was 5,070 Euros, while the
cost of diagnosing SCLC was 3,692 Euros. These diagnos-
tic costs were significantly higher than our findings, but
the study was limited to the cases diagnosed in one teach-
ing hospital in the city of Ourense, so the differences may
reflect specific diagnostic patterns of that hospital, while
our study reflects the multihospital cohort made up of all
public hospitals in Catalonia.The cost of lung cancer treatment presents an import-
ant variability within each stage (mainly in SCLC) due to
the limited number of patients included in the analysis.
Given the low incidence of SCLC, which is only around
15% of the total incident cases of lung cancer, the low
number of SCLC cases included in our study was largely
unavoidable.
One limitation of this study is that only teaching hos-
pitals were included, and therefore a larger number of
patients requiring complex treatment would be expected.
However, we limited our study to teaching hospitals be-
cause of the availability of thoracic surgery units in these
Table 5 Cost of surgery, chemotherapy and radiotherapy treatments (Euros, 2008)
Surgical interventions Chemotherapy treatments Radiotherapy treatments
N Mean cost (Euros) [sd] N Mean cost (Euros) [sd] N Mean cost (Euros) [sd]
NSCLC
Stage I 33 9,566 [1,486] 14 1,949 [2,193] 10 1,275 [901]
Stage II 8 10,177 [1,411] 6 4,604 [4,772] 5 1,308 [692]
Stage III 7 10,228 [1,608] 34 2,911 [5,255] 20 1,298 [907]
Stage IV 3 7,621 [2,707] 68 7,179 [12,465] 35 663 [683]
Unknown 10 9,862 [1,419] 7 15,861 [23,014] 1 900 -
Total 61 9,677 [1,585] 129 5,838 [11,185] 71 977 [825]
SCLC
Limited disease - - - 11 3,087 [2,732] 12 975 [733]
Extensive disease - - - 19 4,372 [11,056] 12 911 [430]
Unknown - - - 1 67 - 0 - -
Total - - - 31 3,778 [8,757] 24 943 [589]
NCC
Stage I 2 8,422 [0] - - - - - -
Stage II - - - - - - - - -
Stage III - - - 3 2,467 [3,378] - - -
Stage IV 1 7,835 - 9 9,012 [11,535] 6 791 [607]
Unknown 1 10,660 - 1 2,335 - - - -
Total 4 8,835 [1,248] 13 6,988 [10,030] 6 791 [607]
NSCLC: non-small cell lung cancer.
SCLC: small cell lung cancer.
NCC: no cytohistologic confirmation.
sd: standard deviation.
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weight of surgery in mean total cost was one of the objec-
tives of this study. In this sense, these hospitals were in-
cluded in order to take into account the overall treatment
of lung cancer. Nonetheless, this sample selection was
considered to be representative of the surgical hospitals.
Moreover, these type of hospitals have detailed informa-
tion on resource use available through electronic records.
Although our study covers a period of three years of
follow-up after diagnosis, it doesn’t provide costing in-
formation by time period. It is worth mentioning that
this limitation is common to all studies conducted to date
given the difficulty in obtaining the information needed to
analyse these parameters. Therefore, further studies are
required in order to investigate cost information by
time period.
Conclusions
This study provides the costs of lung cancer treatment
as calculated from patient file reviews. Chemotherapy and
surgery were the most important components of costs. As
far as we know, ours is the first study that provides
hospital costs of lung cancer treatment based on a review
of patient files from different hospitals in Spain. This costanalysis is a baseline study that will provide a useful source
of information for future studies on cost-effectiveness and
on the budget impact of different therapeutic innovations
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